sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Summary of Product Characteristics last updated on the eMC: 17/09/2007
SPC Gemeprost

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/09/2007 and displayed until Current
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   10/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 7 (Marketing Authorisation Holder): change to MA Holder's address
Updated on 17/08/2006 and displayed until 17/09/2007
Reasons for adding or updating:
  • Change to section 10 (date of (partial) revision of the text
Date of revision of text on the SPC:   09/2005
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change to date in section 10
Updated on 14/03/2006 and displayed until 17/08/2006
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MA number
Updated on 14/01/2002 and displayed until 14/03/2006
Reasons for adding or updating:
  • Change to section 4.3 - Contra-indications
Updated on 16/07/2001 and displayed until 14/01/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 08/12/2000 and displayed until 16/07/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   gemeprost